Klacid Sr

Clarithromycin, the active ingredient in Klacid Sr, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats a range of bacterial infections, including respiratory, sinus, skin and soft‑tissue infections, and is used in Helicobacter pylori eradication regimens.

GNH USA supplies Klacid Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is employed to treat bacterial infections affecting several organ systems. - Community‑acquired pneumonia: effective in treating bacterial pneumonia caused by susceptible organisms. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Skin and soft‑tissue infections: combats susceptible Staphylococcus and Streptococcus species. - Helicobacter pylori eradication regimens: used in combination therapy to eliminate H. pylori infection.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: occasional upset stomach. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: mild cramping. - Altered taste: metallic or bitter sensation. - Headache: transient. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or angioedema. - Clostridioides difficile‑associated diarrhea: persistent watery stools. - Elevated liver enzymes: signs of hepatic stress. - QT interval prolongation: potential cardiac arrhythmias. - Hepatotoxicity: rare liver injury. - Stevens‑Johnson syndrome: severe skin reaction.

Before prescribing Clarithromycin, consider the following safety measures. - Pregnancy: Category B – use only when the benefit outweighs potential risk. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests during therapy. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors that can raise clarithromycin levels. - QT prolongation risk: monitor ECG in patients with existing cardiac disease or electrolyte disturbances. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Clarithromycin interacts with several medicines; clinicians should assess risk before co‑administration.

Major Interactions (Avoid): - Erythromycin, ketoconazole, ritonavir: may markedly increase clarithromycin plasma concentrations. - Cisapride: combined use can cause serious cardiac arrhythmias. - Pimozide: risk of QT prolongation and arrhythmia.

Moderate Interactions (Monitor Closely): - Warfarin: clarithromycin may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: increased serum levels may precipitate toxicity. - Simvastatin, lovastatin: higher risk of myopathy; consider dose reduction or alternative statin.